Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UP421 in Type 1 Diabetes
NCT06239636Phase 1Recruiting
- Sponsor
- Per-Ola Carlsson
- Start
- Mar 2024
- Primary completion
- May 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UP421 in type 1 diabetes mellitus (T1D), sponsored by Per-Ola Carlsson. Primary endpoint: Number of treatment related adverse events at 12 months. Started Mar 2024; status: recruiting.
02
Drugs
UP421
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06239636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06239636.